Bank of New York Mellon Corp Purchases New Shares in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 81,835 shares of the biopharmaceutical company’s stock, valued at approximately $661,000. Bank of New York Mellon Corp owned approximately 0.32% of Inovio Pharmaceuticals at the end of the most recent quarter.

Separately, Vanguard Personalized Indexing Management LLC boosted its position in shares of Inovio Pharmaceuticals by 5.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 6,148 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

INO opened at $5.88 on Tuesday. The firm has a market cap of $152.23 million, a PE ratio of -1.60 and a beta of 0.83. The stock has a 50-day moving average price of $8.23 and a 200-day moving average price of $9.75. Inovio Pharmaceuticals, Inc. has a 1 year low of $3.89 and a 1 year high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. Inovio Pharmaceuticals had a negative return on equity of 99.51% and a negative net margin of 16,238.91%. During the same quarter in the prior year, the company posted ($1.56) EPS. As a group, sell-side analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.64 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INO. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Finally, Royal Bank of Canada dropped their price objective on shares of Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $44.00.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.